Institute Of Molecular Medicine Profile
Key Indicators
- Company Age 25 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 15.00 Cr
as on 12-12-2024
- Revenue -5.85%
(FY 2022)
- Profit -152.81%
(FY 2022)
- Ebitda -75894.52%
(FY 2022)
- Net Worth -4.75%
(FY 2022)
- Total Assets -4.68%
(FY 2022)
About Institute Of Molecular Medicine
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.00 and a paid-up capital of Rs 0.00.
The company has closed loans amounting to ₹15.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Subhasendu Chatterjee, Kishore Bhattacharya, and Swapan Bhattacharya serve as directors at the Company.
- CIN/LLPIN
U24231WB1999NPL090780
- Company No.
090780
- Company Classification
Private Not For Profit Company
- Incorporation Date
17 Dec 1999
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
24 Parganas, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Institute Of Molecular Medicine?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subhasendu Chatterjee  | Director | 17-Dec-1999 | Current |
| Kishore Bhattacharya | Director | 17-Dec-1999 | Current |
| Swapan Bhattacharya | Director | 30-Jun-2000 | Current |
Financial Performance of Institute Of Molecular Medicine.
Institute Of Molecular Medicine, for the financial year ended 2022, experienced Minor drop in revenue, with a 5.85% decrease. The company also saw a substantial fall in profitability, with a 152.81% decrease in profit. The company's net worth dipped by a decrease of 4.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Institute Of Molecular Medicine?
In 2021, Institute Of Molecular Medicine had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Celcius Technologies Private LimitedActive 24 years 10 monthsSubhasendu Chatterjee is a mutual person
- Haldia Riverside Estates Private LimitedActive 26 years 6 months
Subhasendu Chatterjee is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 27 Mar 2008 | ₹12.00 Cr | Satisfied |
Yes Bank Limited Creation Date: 13 Mar 2007 | ₹3.00 Cr | Satisfied |
How Many Employees Work at Institute Of Molecular Medicine?
Unlock and access historical data on people associated with Institute Of Molecular Medicine, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Institute Of Molecular Medicine, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Institute Of Molecular Medicine's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
